Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04824040 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF

Study acronym: DYSF-RUS
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 25, 2024 to Feb 25, 2027
    • Study completion date: Jul 2024 to Jul 2027
    • Publications: 2 to 6
    • Study title expanded, about 2 words
    v4
  2. Primary completion date: Feb 25, 2022 to Feb 25, 2024
    • Study completion date: Jul 2022 to Jul 2024
    • Study site revised
    • Collaborator revised
    v3
  3. Publications: details revised at 1 of 2 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate specific characteristics of phenotype, immune status, molecular and genetic as well as morphological characteristics of adult patients with limb-girdle muscular dystrophy R2 in various regions of the Russian Federation.
Trial Details
NCT Number NCT04824040
Lead Sponsor Artgen Biotech
Collaborators: Genotarget
Conditions
(from sponsor)		 Dysferlinopathy, Miyoshi Myopathy, LGMDR2, DMAT
Related terms Dysferlinopathy, Limb-girdle muscular dystrophy, type 2B, Miyoshi myopathy
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov